论文部分内容阅读
目的 观察玻璃体内注射康柏西普治疗视网膜静脉阻塞继发性黄斑水肿的效果.方法 对山西省眼科医院2016年1月至2018年12月视网膜静脉阻塞继发性黄斑水肿的52例进行回顾性病例对照研究.患者均按3+按需(3+PRN)注射的方法眼内注射康柏西普0.05 mL(0.5 mg),随访6个月.结果 治疗后1、2、3及6个月的最佳矫正视力均优于治疗前(t=13.010、15.980、7.530、4.051,均P＜0.05);治疗后黄斑中心区厚度均低于治疗前(t=17.92、12.32、5.58、0.41,均P＜0.05).治疗及随访期间患者均未出现玻璃体积血、视网膜脱离、持续高眼压或眼内炎等严重并发症.结论 玻璃体内注射康柏西普治疗视网膜静脉阻塞继发的黄斑水肿效果良好,可以改善视力和减轻黄斑水肿.“,”Objective To observe the efficacy of intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion (RVO).Methods A case-control retrospective study.The data of 52 patients with macular edema secondary to RVO from Jan.2016 to Dec.2018 in Shanxi Province Eye Hospital were analyzed.All patients were treated with intravitreal conbercept injection,dose of 0.5 mg or 0.05 mL,in the 3+pro renata (PRN) project.The followed up time was 6 months.Results The best corrected visual acuity (BCVA) at 1,2,3 and 6 months after treatment were better than that before treatment (t=13.010,15.980,7.530,4.051,P＜0.05).The thickness of central macula after treatment was lower than that before treatment (t=17.92,12.32,5.58,0.41,P＜0.05).During the treatment and follow-up,there was no serious complication such as vitreous hemorrhage,retinal detachment,persistent high intraocular pressure or endophthalmitis.Conclusion Intravitreal injection of conbercept is effective in the treatment of macular edema secondary to RVO,which can improve vision and reduce macular edema.